- Home
- CFND vs ANVS Comparison
CFND vs ANVS Comparison
Compare CFND & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFND | ANVS |
|---|---|---|
| Founded | N/A | 2008 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 111.3M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CFND | ANVS |
|---|---|---|
| Price | $4.98 | $3.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | N/A | ★ 4.0M |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $1.11 |
| 52 Week High | N/A | $6.37 |
Technical Indicators
Market Signals| Indicator | CFND | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.44 |
| Support Level | N/A | $4.12 |
| Resistance Level | N/A | $4.24 |
| Average True Range (ATR) | 0.00 | 0.47 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 0.00 | 11.67 |
Price Performance
Historical ComparisonAbout CFND C1 Fund Inc.
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.